Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta
Vir Biotechnology announced that its pivotal Phase 3 ECLIPSE 1 trial of monthly subcutaneous elebsiran plus tobevibart in chronic hepatitis delta met all endpoints, with a 44% primary-endpoint response rate (undetectable virus plus ALT normalization) versus 0% in the delayed-treatment arm. The key secondary endpoint was also met at 79% undetectable virus versus 0%, all patients achieved virologic response at Week 24, and the regimen was well tolerated with no discontinuations across 124 enrolled patients. Data from ECLIPSE 2 and 3 are expected in Q1 2027 and will support a comprehensive U.S.
Key figures
- Drug Name
- elebsiran and tobevibart (for chronic hepatitis delta)
- Phase Of Trial
- Pivotal Phase 3 (ECLIPSE 1)
- P value
- <0.0001
- Enrolled patients
- 124
- Fda submission timing
- mid-2027
- Eclipse 2 3 data timing
- Q1 2027
- Virologic response week 24
- 100%
- Primary endpoint response rate
- 44%
- Key secondary endpoint response rate
- 79%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.